C19orf53 Inhibitors
C19orf53 inhibitors encompass a range of chemical compounds that act upon various cellular signaling pathways to exert their inhibitory effects on the protein C19orf53. LY294002 and Wortmannin, by specifically targeting PI3K, lead to a reduction in AKT phosphorylation, a key activator within the PI3K/AKT pathway that is known to propagate downstream signaling affecting C19orf53 activity. Similarly, Rapamycin directly targets mTORC1, a central regulator of cell growth and metabolism, which indirectly suppresses C19orf53 activity by disrupting mTORC1-mediated signaling. Torin 1 and PP242 extend these inhibitory effects to mTORC2 as well, offering a broader inhibition of mTOR signaling that encompasses the regulatory scope of C19orf53. The dual PI3K/mTOR inhibitor PF-04691502 and the mTOR kinase inhibitor AZD8055 also decrease C19orf53 activity by blocking the PI3K/AKT/mTOR pathway at multiple nodes, further diminishing the protein's activity.
Further into the signaling cascade, PD98059 and U0126 are employed as MEK inhibitors, which indirectly inhibit the MAPK/ERK pathway, subsequently decreasing the activity of proteins regulated by thispathway, which may include C19orf53. The inhibition of MAPK/ERK signaling can dampen the phosphorylation status and thus the functional state of C19orf53. SB203580 and SP600125, which selectively inhibit p38 MAPK and JNK respectively, alter the stress-activated signaling pathways that can impact proteins like C19orf53 that may be responsive to such stimuli. The specificity of PF-4708671 towards p70 S6 kinase 1 (S6K1) again highlights the multiplicity of mTOR pathway targeting, where inhibition of S6K1 leads to reduced protein synthesis and growth signals that can affect the activity of downstream proteins, including C19orf53.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of phosphatidylinositol 3-kinase (PI3K). By inhibiting PI3K, LY294002 prevents the phosphorylation and activation of AKT. C19orf53 is a downstream effector in the PI3K/AKT pathway, and its activity can be inhibited when AKT activation is blocked. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that binds to FKBP12 and specifically inhibits mTORC1. C19orf53, which is a protein downstream of the mTOR pathway, can have its activity reduced due to the suppression of mTORC1-mediated signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An irreversible inhibitor of PI3K. Wortmannin suppresses the PI3K/AKT pathway, leading to reduced phosphorylation of downstream targets including C19orf53, thus inhibiting its activity. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
A selective ATP-competitive mTOR inhibitor that can inhibit both mTORC1 and mTORC2. By inhibiting these complexes, Torin 1 interferes with downstream signaling that regulates C19orf53 function. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
A selective inhibitor of mTOR kinase activity, affecting both mTORC1 and mTORC2. PP242's inhibition of mTOR signaling can lead to decreased activity of C19orf53 due to the disruption of downstream effects. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
An ATP-competitive inhibitor of mTOR kinase, inhibiting both mTORC1 and mTORC2. AZD8055's action results in inhibition of downstream targets in the mTOR pathway, including C19orf53. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK1/2 which are upstream of ERK1/2 in the MAPK pathway. By inhibiting MEK, PD98059 indirectly inhibits downstream signaling that may regulate C19orf53 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK. By inhibiting p38 MAPK, SB203580 can lead to a reduction in the activity of proteins like C19orf53 that may be regulated by stress-activated pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK), leading to decreased activity of transcription factors regulated by JNK, which may include factors controlling C19orf53 function. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
A specific inhibitor of the p70 S6 kinase 1 (S6K1). As S6K1 is downstream of mTORC1, inhibiting S6K1 with PF-4708671 can lead to reduced signaling to downstream proteins such as C19orf53. | ||||||